|
|
|
16.06.25 - 14:06
|
908 Devices Appoints Christopher D. Brown to its Board of Directors (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately.
Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (Nasdaq: AAPL) leading investigations in future-gen health technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific Inc. (NYSE: TMO) and from 2005 until 2010 he led product development and engineering at Ahura Scientific, which was acquired by Thermo Fi...
|
|
|
|
|
|
|
27.05.25 - 13:33
|
Repligen Announces Publication of the Company′s 2024 Corporate Sustainability Report (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “Perspectives on Progress”, this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two key reporting frameworks: the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB), now part of the IFRS Sustainability Alliance....
|
|
|
22.05.25 - 13:36
|
Repligen Corporation to Present at William Blair Growth Conference (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT....
|
|
|
|
|
13.05.25 - 13:06
|
908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook (Business Wire)
|
|
|
Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025.
“We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions,” said Kevin J. Knopp, CEO and Co-founder. “With a sharpened focus, a strengthened financial position, and macro trends increasingly developing into tailwinds, we remain fully committed to our adjusted EBITDA profitability target by the fourth quarter and expanding our leadership in frontline chemical detection.”
Recent Highlights
Announced divestiture of bioprocessing product portfolio to Repligen Corporati...
|
|
|
|
|
|
|
|
|
|
|
29.04.25 - 13:33
|
Repligen Reports First Quarter 2025 Financial Results (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025....
|
|
|
|
|
|
|
|
|
|
|
08.04.25 - 13:33
|
Repligen Appoints Jacob Johnson As Vice President Investor Relations (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
